Prostate Cancer Clinical Trial
|Source||Sir Mortimer B. Davis - Jewish General Hospital|
|Status||Enrolling by invitation|
|Start date||September 2016|
|Completion date||December 2020|
The objectives of this study are to confirm the safety and efficacy of FCH-PET/CT and to establish our ability to reproduce results from the literature using FCH-PET/CT as a diagnostic and decision making tool in the management in two predefined groups of prostate cancer patients, specifically, biochemical recurrence and high risk staging. The primary endpoints of the study are the incidence of adverse events (AE) in the study population up to 24 hours following the scan, and the sensitivity and specificity of FCH-PET/CT vs CT on a per-patient and per-lesion basis.
Background Prostate cancer is the second leading cause of cancer death in North American men
older than 50 years. Positron emission tomography / computer tomography (PET/CT) is a
nuclear medicine procedure based on the measurement of positron emission from radiolabeled
tracer molecules. A common radiotracer in use today is 18F-fluoromethylcholine (aka
fluorocholine or FCH) which is a radiolabeled choline derivative. Imaging with FCH-PET/CT
can be used to characterize and localize prostate cancer in vivo. There is extensive data in
the literature showing the value of FCH-PET/CT imaging in accurately staging and restaging
prostate cancer. FCH-PET/CT is standard of care in many European countries.
Study Objectives The objectives of this study are to confirm the safety and efficacy of FCH-PET/CT and to establish our ability to reproduce results from the literature using FCH-PET/CT as a diagnostic and decision making tool in the management in two predefined groups of prostate cancer patients, specifically, biochemical recurrence and high risk staging. The primary endpoints of the study are the incidence of adverse events (AE) in the study population up to 24 hours following the scan, and the sensitivity and specificity of FCH-PET/CT vs CT on a per-patient and per-lesion basis.
Study Design This will be a multi-center open label study in which one (1) FCH-PET/CT will be performed on study participants. A PET/CT scan takes 2-3 hours.
Safety FCH-PET/CT exhibits favorable dosimetry, delivering organ doses that are comparable to or lower than those delivered by 18F-FDG. The safety of FCH is not disputed and we expect the number of adverse events in our study to be zero.
Sample Size and Recruitment Target enrollment is 1500 patients. This will be sufficient to detect AE with a prevalence of 0.3% with 99% confidence. For efficacy endpoints, approximately 500 subjects would provide 90% power at the alpha=0.05 one-sided level of significance that the specificity and sensitivity will be superior to the specificity and sensitivity under the null hypothesis. Patients will be recruited by urologists in the clinical setting. Initial contact and consent will be by the department of urology.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
|Recruiting||NCT03177759 - Living With Prostate Cancer (LPC)||N/A|
|Completed||NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data||N/A|
|Not yet recruiting||NCT03160365 - Innovative Planning and Guidance System for Prostate Focal Brachytherapy||N/A|
|Active, not recruiting||NCT02124668 - A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy||Phase 2|
|Completed||NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis||N/A|
|Active, not recruiting||NCT00779168 - White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy||Phase 1|
|Recruiting||NCT01990196 - Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer||Phase 2|
|Recruiting||NCT02766543 - Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer||Phase 2|
|Not yet recruiting||NCT03157947 - Culturally Tailored Decision Aid for Hispanic Patients Diagnosed With Prostate Cancer||N/A|
|Recruiting||NCT02747342 - A Phase 1 Trial of SHR3680 in Prostate Cancer as Monotherapy||Phase 1|
|Recruiting||NCT02886598 - Safety and Efficacy of Firmagon® (Degarelix) for Injection||N/A|
|Recruiting||NCT02918357 - Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence||Phase 2/Phase 3|
|Recruiting||NCT02543255 - Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)||Phase 2|
|Recruiting||NCT02906241 - PACCT: Partnering Around Cancer Clinical Trials||N/A|
|Recruiting||NCT02917161 - Prostatic Artery Embolization Before Radical Prostatectomy in Prostate Cancer: A Proof-of-concept Study||N/A|
|Recruiting||NCT02919111 - Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients||Phase 2/Phase 3|
|Recruiting||NCT02916537 - A Phase 1 Trial for Safety and Imaging Evaluation of CTT1057, a Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA)||Phase 1|
|Recruiting||NCT02911922 - Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer||N/A|
|Recruiting||NCT02766686 - Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons||N/A|
|Not yet recruiting||NCT02886546 - Utility of Dynamic Variables Measured by Calibrated Pulse Contour Analysis of Oesophageal Doppler Monitor for Predicting Fluid Responsiveness During Robot-Assisted Laparoscopic Prostatectomy||N/A|